Quarterly ResultAug 5, 2026, 04:10 PM
Sarepta YTD Net Income $326.07M; Q2 Net Loss $(4.89)M
AI Summary
Sarepta Therapeutics reported a net income of $326.07 million for the six months ended June 30, 2026, a significant improvement from a net loss of $(250.62) million in the prior year period. However, the second quarter of 2026 saw a net loss of $(4.89) million, compared to a net income of $196.89 million in Q2 2025. Total revenues for the six months decreased to $1.13 billion, while Q2 revenues were $401.25 million. The company recognized $365 million in collaboration revenue from Roche, including $325 million from a declined option, and continues to address regulatory pathways for ELEVIDYS.
Key Highlights
- YTD 2026 net income was $326.07 million, up from a net loss of $(250.62) million in YTD 2025.
- Q2 2026 net loss was $(4.89) million, compared to a net income of $196.89 million in Q2 2025.
- YTD 2026 total revenues decreased to $1.13 billion from $1.36 billion in YTD 2025.
- Q2 2026 total revenues were $401.25 million, down from $611.09 million in Q2 2025.
- Collaboration revenue from Roche totaled $365 million YTD 2026, including $325 million from a declined option.
- Net cash used in operating activities improved to $(5.61) million YTD 2026 from $(322.10) million YTD 2025.
- Cash, cash equivalents, and restricted cash stood at $581.27 million as of June 30, 2026.
- Sarepta continues clinical trials for ELEVIDYS to resume dosing for non-ambulatory patients.
Price Impact
More from SRPT